Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Operations (2020 - 2025)

Historic Cash from Operations for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $15.8 million.

  • GeneDx Holdings' Cash from Operations rose 45874.86% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 16015.12%. This contributed to the annual value of -$28.5 million for FY2024, which is 8418.18% up from last year.
  • Latest data reveals that GeneDx Holdings reported Cash from Operations of $15.8 million as of Q3 2025, which was up 45874.86% from $10.4 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Cash from Operations ranged from a high of $15.8 million in Q3 2025 and a low of -$88.4 million during Q3 2022
  • In the last 5 years, GeneDx Holdings' Cash from Operations had a median value of -$41.2 million in 2023 and averaged -$35.9 million.
  • In the last 5 years, GeneDx Holdings' Cash from Operations tumbled by 1929268.69% in 2021 and then soared by 45874.86% in 2025.
  • Quarter analysis of 5 years shows GeneDx Holdings' Cash from Operations stood at -$52.0 million in 2021, then fell by 24.37% to -$64.7 million in 2022, then soared by 53.82% to -$29.9 million in 2023, then surged by 89.34% to -$3.2 million in 2024, then surged by 595.35% to $15.8 million in 2025.
  • Its Cash from Operations stands at $15.8 million for Q3 2025, versus $10.4 million for Q2 2025 and $10.2 million for Q1 2025.